AU2015284236B2 - Targeted conjugates and particles and formulations thereof - Google Patents

Targeted conjugates and particles and formulations thereof Download PDF

Info

Publication number
AU2015284236B2
AU2015284236B2 AU2015284236A AU2015284236A AU2015284236B2 AU 2015284236 B2 AU2015284236 B2 AU 2015284236B2 AU 2015284236 A AU2015284236 A AU 2015284236A AU 2015284236 A AU2015284236 A AU 2015284236A AU 2015284236 B2 AU2015284236 B2 AU 2015284236B2
Authority
AU
Australia
Prior art keywords
conjugate
acid
pct
particle
poly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2015284236A
Other languages
English (en)
Other versions
AU2015284236A1 (en
Inventor
Rossitza G. Alargova
Patrick Rosaire BAZINET
Mark T. Bilodeau
Craig A. Dunbar
Sudhakar Kadiyala
Patrick Lim Soo
Rajesh R. Shinde
Beata Sweryda-Krawiec
Brian H. White
Richard Wooster
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
TVA ABC LLC
Original Assignee
TVA ABC LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by TVA ABC LLC filed Critical TVA ABC LLC
Publication of AU2015284236A1 publication Critical patent/AU2015284236A1/en
Application granted granted Critical
Publication of AU2015284236B2 publication Critical patent/AU2015284236B2/en
Priority to AU2018204037A priority Critical patent/AU2018204037B2/en
Assigned to TVA (ABC), LLC reassignment TVA (ABC), LLC Request for Assignment Assignors: TARVEDA THERAPEUTICS, INC.
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AU2015284236A 2014-06-30 2015-06-30 Targeted conjugates and particles and formulations thereof Ceased AU2015284236B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2018204037A AU2018204037B2 (en) 2014-06-30 2018-06-07 Targeted conjugates and particles and formulations thereof

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201462019001P 2014-06-30 2014-06-30
US62/019,001 2014-06-30
US201462077487P 2014-11-10 2014-11-10
US62/077,487 2014-11-10
US201562150413P 2015-04-21 2015-04-21
US62/150,413 2015-04-21
PCT/US2015/038569 WO2016004048A2 (en) 2014-06-30 2015-06-30 Targeted conjugates and particles and formulations thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2018204037A Division AU2018204037B2 (en) 2014-06-30 2018-06-07 Targeted conjugates and particles and formulations thereof

Publications (2)

Publication Number Publication Date
AU2015284236A1 AU2015284236A1 (en) 2016-12-22
AU2015284236B2 true AU2015284236B2 (en) 2018-03-08

Family

ID=55020088

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2015284236A Ceased AU2015284236B2 (en) 2014-06-30 2015-06-30 Targeted conjugates and particles and formulations thereof
AU2018204037A Ceased AU2018204037B2 (en) 2014-06-30 2018-06-07 Targeted conjugates and particles and formulations thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2018204037A Ceased AU2018204037B2 (en) 2014-06-30 2018-06-07 Targeted conjugates and particles and formulations thereof

Country Status (15)

Country Link
US (4) US9750818B2 (enrdf_load_stackoverflow)
EP (1) EP3160518A4 (enrdf_load_stackoverflow)
JP (3) JP6602834B2 (enrdf_load_stackoverflow)
KR (2) KR20190143491A (enrdf_load_stackoverflow)
CN (2) CN106573077B (enrdf_load_stackoverflow)
AU (2) AU2015284236B2 (enrdf_load_stackoverflow)
BR (1) BR212016030926U2 (enrdf_load_stackoverflow)
CA (1) CA2953371C (enrdf_load_stackoverflow)
IL (1) IL249647B (enrdf_load_stackoverflow)
MX (1) MX379365B (enrdf_load_stackoverflow)
PH (1) PH12017500023A1 (enrdf_load_stackoverflow)
RU (1) RU2695220C2 (enrdf_load_stackoverflow)
SG (1) SG11201610880RA (enrdf_load_stackoverflow)
WO (1) WO2016004048A2 (enrdf_load_stackoverflow)
ZA (1) ZA201608432B (enrdf_load_stackoverflow)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190015350A1 (en) 2013-02-05 2019-01-17 Anp Technologies, Inc. Nanoparticles Containing a Taxane and their Use
US9533054B2 (en) * 2013-03-11 2017-01-03 Shanghai Jiao Tong University Amphiphilic drug-drug conjugates for cancer therapy, compositions and methods of preparation and uses thereof
RU2695220C2 (ru) * 2014-06-30 2019-07-22 Тарведа Терапьютикс, Инк. Нацеленные конъюгаты и частицы и их составы
KR20180021742A (ko) * 2015-06-30 2018-03-05 타베다 세라퓨틱스, 인코포레이티드 표적화된 접합체 및 이의 입자 및 제형
CN107920985B (zh) * 2015-07-15 2022-03-01 塞拉特药物股份有限公司 改善的纳米颗粒递送系统
CN108473538B (zh) * 2015-10-28 2022-01-28 塔弗达治疗有限公司 Sstr靶向缀合物及其颗粒和制剂
US10039801B2 (en) 2016-02-16 2018-08-07 Strongbridge Ireland Limited Pharmaceutical compositions of water soluble peptides with poor solubility in isotonic conditions and methods for their use
WO2017161096A1 (en) * 2016-03-16 2017-09-21 Tarveda Therapeutics, Inc. Antibody mimic conjugates and particles
US20200078468A1 (en) * 2016-04-13 2020-03-12 Tarveda Therapeutics, Inc. Neurotensin receptor binding conjugates and formulations thereof
WO2017210246A2 (en) * 2016-05-31 2017-12-07 Tarveda Therapeutics, Inc. Penicillamine conjugates and particles and formulations thereof
EP3507295A1 (en) * 2016-08-31 2019-07-10 Mireca Medicines GmbH New polymer linked multimers of guanosine-3', 5'-cyclic monophosphates
KR20190075938A (ko) * 2016-10-28 2019-07-01 타베다 세라퓨틱스, 인코포레이티드 Sstr-표적화된 접합체 및 이의 입자 및 제형
WO2018222987A1 (en) * 2017-06-01 2018-12-06 Tarveda Therapeutics, Inc. Targeted constructs
CA3069159A1 (en) * 2017-07-11 2019-01-17 Sustained Nano Systems Llc Hypercompressed pharmaceutical formulations
CN107422021B (zh) * 2017-07-14 2019-11-19 北京朗阅科技有限公司 琼脂糖胶囊及其制备方法与应用
EP3672618A4 (en) * 2017-08-25 2021-07-07 Nal Pharmaceutical Group Limited COMPOSITIONS AND METHODS OF ADMINISTRATION OF PHARMACOLOGICAL AGENTS
WO2019084377A1 (en) * 2017-10-27 2019-05-02 Tarveda Therapeutics, Inc. SSTR TARGETING CONJUGATES AND FORMULATIONS THEREOF
JP2021506797A (ja) * 2017-12-14 2021-02-22 ターベダ セラピューティクス インコーポレイテッドＴａｒｖｅｄａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． Ｈｓｐ９０標的化コンジュゲート及びその製剤
AU2019277656A1 (en) * 2018-06-01 2021-01-07 Tva (Abc), Llc Combination therapy
CN109124096B (zh) * 2018-08-23 2021-08-06 广州百隆威尔精密五金制品有限公司 一种升降橱柜
CN116920115A (zh) 2018-12-17 2023-10-24 荣昌生物制药(烟台)股份有限公司 一种用于抗体药物偶联物的连接子及其应用
WO2020191011A1 (en) * 2019-03-18 2020-09-24 The Trustees Of Columbia University In The City Of New York Non-hydrolyzable, non-cleavable, stable linkers for precision therapeutics and uses thereof
CN109848440A (zh) * 2019-04-10 2019-06-07 燕山大学 一种钯纳米立方体的制备方法
AU2020307561A1 (en) * 2019-06-25 2022-01-20 Tva (Abc), Llc SSTR-targeted conjugates and formulations thereof
CN112250647A (zh) * 2020-06-30 2021-01-22 浙江大学 紫杉烷类药物前体、制备方法和应用
JP2024504512A (ja) 2020-12-21 2024-01-31 コーネル・ユニバーシティー ペプチド連結薬物送達系
WO2022174171A1 (en) * 2021-02-15 2022-08-18 Anp Technologies, Inc. Pharmaceutical composition containing taxane nanoaggregates and use thereof
TW202302073A (zh) * 2021-03-18 2023-01-16 予宇生技股份有限公司 包含帶電脂質的脂質製劑的組合物及製備方法
US20240189241A1 (en) * 2021-04-01 2024-06-13 R.P. Scherer Technologies, Llc Phospholipids as anion chelating agents in pharmaceutical formulations
IT202100014330A1 (it) * 2021-06-01 2022-12-01 The Ubeauty Com Llc Prodotto per la cura della pelle e procedimento per la sua realizzazione.
CN118005545B (zh) * 2024-01-04 2025-02-18 兰州大学 小分子抗菌肽模拟物及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004093807A2 (en) * 2003-04-22 2004-11-04 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Somatostatin vectors
US20050169933A1 (en) * 2003-10-10 2005-08-04 Immunogen, Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5595756A (en) * 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
US5702717A (en) * 1995-10-25 1997-12-30 Macromed, Inc. Thermosensitive biodegradable polymers based on poly(ether-ester)block copolymers
US5843903A (en) 1995-11-27 1998-12-01 The Administrators Of The Tulane Educational Fund Targeted cytotoxic anthracycline analogs
AT405906B (de) 1997-03-14 1999-12-27 Irene Dr Virgolini Radiomarkierte somatostatin rezeptor-liganden zur diagnose und therapie
US6358491B1 (en) * 1999-08-27 2002-03-19 Berlex Laboratories, Inc. Somatostatin analogs
EP1225916A1 (en) * 1999-11-01 2002-07-31 University Technology Corporation Compositions and methods for controlled-release delivery and increased potency of pharmaceuticals via hydrophobic ion-pairing
AU4267700A (en) * 2000-01-13 2001-07-19 Academia Sinica Application of somatostatin analogs to specific delivery of anti-tumor drugs into tumor cells
DE10006572A1 (de) * 2000-02-14 2001-08-23 Deutsches Krebsforsch Oligonucleotid-Konjugate
FR2824563B1 (fr) * 2001-05-10 2004-12-03 Bio Merieux Particules composites, conjugues derives, procede de preparation et applications
US6441163B1 (en) 2001-05-31 2002-08-27 Immunogen, Inc. Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
US8877901B2 (en) * 2002-12-13 2014-11-04 Immunomedics, Inc. Camptothecin-binding moiety conjugates
WO2003072754A2 (en) 2002-02-27 2003-09-04 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Conjugates of ligand, linker and cytotoxic agent and related compositions and methods of use
CN102133407A (zh) 2002-03-01 2011-07-27 图兰恩教育基金管理人 治疗剂或细胞毒性剂与生物活性肽的偶联物
PT2277551E (pt) * 2002-09-06 2013-08-22 Cerulean Pharma Inc Polímeros à base de ciclodextrina para a administração de medicamentos ligados por ligação covalente
TWI260228B (en) * 2002-12-31 2006-08-21 Ind Tech Res Inst Delivery carrier of presenting cell of somatostatin receptor
CA2523605A1 (en) 2003-03-10 2004-09-23 Charles W. Spangler Targeted agents for both photodiagnosis and photodynamic therapy
US7276497B2 (en) 2003-05-20 2007-10-02 Immunogen Inc. Cytotoxic agents comprising new maytansinoids
WO2004103272A2 (en) * 2003-05-20 2004-12-02 Immunogen, Inc. Improved cytotoxic agents comprising new maytansinoids
JP4318985B2 (ja) * 2003-08-21 2009-08-26 日本メジフィジックス株式会社 ソマトスタチンアナログ誘導体およびその利用
WO2006086733A2 (en) * 2005-02-11 2006-08-17 Immunogen, Inc. Process for preparing maytansinoid antibody conjugates
CN102989000B (zh) 2005-08-24 2016-04-20 伊缪诺金公司 制备美登木素生物碱抗体缀合物的方法
ES2416136T3 (es) * 2005-09-26 2013-07-30 Medarex, Inc. Conjugados de anticuerpo-fármaco y su uso
EP1864682A1 (en) 2006-06-09 2007-12-12 Sanofi-Aventis Leptomycin derivatives
US10925977B2 (en) * 2006-10-05 2021-02-23 Ceil>Point, LLC Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications
EP2081553B1 (en) * 2006-10-06 2020-08-12 Amgen Inc. Stable antibody formulations
HUE035184T2 (en) 2008-03-18 2018-05-02 Genentech Inc Combinations of an anti-HER2 antibody-drug conjugate and docetaxel
WO2009134952A2 (en) 2008-04-30 2009-11-05 Immunogen, Inc Potent conjugates and hydrophilic linkers
BRPI0912230A2 (pt) * 2008-05-06 2017-08-22 Glaxo Group Ltd Método para encapsular agentes biologicamente ativos em um carreador particulado, carreador particulado, e, composição farmacêutica
CA2722418C (en) * 2008-05-13 2013-09-17 Irm Llc Fused nitrogen containing heterocycles and compositions thereof as kinase inhibitors
CA2737040C (en) * 2008-09-19 2017-05-02 Nektar Therapeutics Polymer conjugates of therapeutic peptides
FR2945211A1 (fr) 2009-05-06 2010-11-12 Sanofi Aventis Combinaison antitumorale comprenant la cabazitaxel et la capecitabine
PL2449379T3 (pl) * 2009-07-02 2017-12-29 Sloan-Kettering Institute For Cancer Research Fluorescencyjne nanocząstki na bazie krzemionki
WO2011078250A1 (ja) * 2009-12-25 2011-06-30 独立行政法人理化学研究所 生体内にて標的組織に指向する放射標識化合物およびその利用
CA2793715A1 (en) * 2010-04-30 2011-11-03 Sanwa Kagaku Kenkyusho Co., Ltd. Peptide for improving in vivo stability of physiologically active substance or the like and physiologically active substance with improved in vivo stability
TW201302793A (zh) * 2010-09-03 2013-01-16 Glaxo Group Ltd 新穎之抗原結合蛋白
WO2012033901A2 (en) * 2010-09-08 2012-03-15 The Board Of Regents Of The University Of Texas System Somatostatin receptor-based cancer therapy
RU2013140291A (ru) * 2011-03-01 2015-04-10 ДжиИ ХЕЛТКЕР ЛИМИТЕД Меченые радиоактивной меткой аналоги октреотата в качестве рет-индикаторов
WO2012138911A2 (en) * 2011-04-05 2012-10-11 The Administrators Of The Tulane Educational Fund Conjugates of anti-hiv drugs and somatostatin analogs
WO2012145112A2 (en) 2011-04-18 2012-10-26 Immunogen, Inc. Novel maytansinoid derivatives with sulfoxide linker
WO2012156920A1 (en) * 2011-05-16 2012-11-22 Koninklijke Philips Electronics N.V. Bio-orthogonal drug activation
SG10201605041VA (en) 2011-06-21 2016-08-30 Immunogen Inc Novel maytansinoid derivatives with peptide linker and conjugates thereof
WO2013130684A1 (en) * 2012-02-27 2013-09-06 Amunix Operating Inc. Xten-folate conjugate compositions and methods of making same
HK1211468A1 (en) * 2012-09-17 2016-05-27 Pfizer Inc. Therapeutic nanoparticles comprising a therapeutic agent and methods of making and using same
HK1219422A1 (zh) 2013-02-28 2017-04-07 Immunogen, Inc. 包含细胞结合剂及细胞毒素剂的轭合物
US20150238631A1 (en) 2013-10-15 2015-08-27 The California Institute For Biomedical Research Chimeric antigen receptor t cell switches and uses thereof
RU2695220C2 (ru) * 2014-06-30 2019-07-22 Тарведа Терапьютикс, Инк. Нацеленные конъюгаты и частицы и их составы

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004093807A2 (en) * 2003-04-22 2004-11-04 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Somatostatin vectors
US20050169933A1 (en) * 2003-10-10 2005-08-04 Immunogen, Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
SUN, L-C et al., 'Somatostatin Receptor-Targeted Anti-Cancer Therapy', Current Drug Delivery. 2011, vol. 8, issue 1, pages 2-10. *
XIAO et al., "Co-delivery of doxorubicin and siRNA using octreotideconjugated gold nanorods for targeted neuroendocrine cancer therapy", Nanoscale, (2012), vol. 4, no. 22, page 21 pages 7185-7193. *

Also Published As

Publication number Publication date
ZA201608432B (en) 2019-07-31
US20180000959A1 (en) 2018-01-04
EP3160518A2 (en) 2017-05-03
JP2021175757A (ja) 2021-11-04
JP2017520585A (ja) 2017-07-27
CN106573077B (zh) 2019-07-30
SG11201610880RA (en) 2017-01-27
RU2016151859A (ru) 2018-08-06
CN106573077A (zh) 2017-04-19
BR212016030926U2 (pt) 2018-05-29
US11458206B2 (en) 2022-10-04
RU2016151859A3 (enrdf_load_stackoverflow) 2018-08-06
US20170095569A1 (en) 2017-04-06
JP2020063241A (ja) 2020-04-23
US10322191B2 (en) 2019-06-18
US10624967B2 (en) 2020-04-21
AU2018204037B2 (en) 2020-03-26
MX2017000080A (es) 2017-05-30
US20170312245A1 (en) 2017-11-02
CN110478495A (zh) 2019-11-22
AU2018204037A1 (en) 2018-06-21
US20200206356A1 (en) 2020-07-02
JP6602834B2 (ja) 2019-11-06
CA2953371C (en) 2021-08-24
CA2953371A1 (en) 2016-01-07
EP3160518A4 (en) 2018-05-23
MX379365B (es) 2025-03-11
KR20190143491A (ko) 2019-12-30
US9750818B2 (en) 2017-09-05
IL249647B (en) 2021-04-29
IL249647A0 (en) 2017-02-28
WO2016004048A3 (en) 2016-03-24
AU2015284236A1 (en) 2016-12-22
PH12017500023A1 (en) 2017-05-15
KR102062025B1 (ko) 2020-01-03
RU2695220C2 (ru) 2019-07-22
JP6932389B2 (ja) 2021-09-08
KR20170020923A (ko) 2017-02-24
WO2016004048A2 (en) 2016-01-07

Similar Documents

Publication Publication Date Title
US11458206B2 (en) Targeted conjugates and particles and formulations thereof
US20220288229A1 (en) Targeted conjugates encapsulated in particles and formulations thereof
US20220096646A1 (en) Sstr-targeted conjugates and particles and formulations thereof
US11510910B2 (en) HSP90 targeted conjugates and particles and formulations thereof
US20190125888A1 (en) Targeted conjugates and particles and formulations thereof

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: TVA (ABC), LLC

Free format text: FORMER OWNER(S): TARVEDA THERAPEUTICS, INC.

MK14 Patent ceased section 143(a) (annual fees not paid) or expired